FILE PHOTO: Chinese vaccine maker CanSino Biologics' sign is pictured on its building in Tianjin, China November 20, 2018. Picture taken November 20, 2018. REUTERS/Stringer
BEIJING (Reuters) - China’s vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country’s intellectual property regulator.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People’s Daily reported on Sunday.
The paper cited documents published by China’s National Intellectual Property Administration saying that the patent was issued on Aug. 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino’s Hong Kong shares rose around 14% in Monday’s morning session. Its Shanghai shares rose by 6.6% as of midday.
Reporting by Sophie Yu and Brenda Goh; Editing by Tom Hogue
World - Latest - Google News
August 17, 2020 at 11:10AM
https://ift.tt/3aww1cQ
China grants country's first COVID-19 vaccine patent to CanSino: state media - Reuters
World - Latest - Google News
https://ift.tt/2SeTG7d
Bagikan Berita Ini
0 Response to "China grants country's first COVID-19 vaccine patent to CanSino: state media - Reuters"
Post a Comment